MR
Merus
MRUS · NASDAQ
$90.00 +0.00% (+$0.00)
Market Cap $6.83B
P/E Ratio -
Div. Yield -
ROE 48.76%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 133.38x
P/B 10.32x
P/E N/A
Growth
80 /100
Growing Rev. growth 11.85%
Book val. growth 23.46%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 217.50%
FCF margin 621.16%
Net margin 654.44%
Quality
1 /100
Poor ROIC 48.81%
Asset turnover 0.07x
ROE 48.76%
Debt
95 /100
Low Debt/Equity 0.02x
Net debt/EBITDA 0.94x
Current ratio 7.97x
Stability
30 /100
Unstable Beta 1.06x
Profitable years 0
Rev. volatility 50.15%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MRUS
Online
About the company
Merus N.V. is a Dutch biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company is particularly known for its bispecific antibody technology, designed to selectively activate the immune system against cancer cells. Merus N.V. concentrates on developing treatments that can offer new hope to patients suffering from various types of cancer, including those who have failed other therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
260
Headquarters
Utrecht